...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis
【24h】

Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis

机译：通过白蛋白-胆红素评分预测原发性胆源性胆管炎的无移植存活率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Albumin–bilirubin (ALBI) grade is defined using the ALBI score, which is calculated based on total serum bilirubin and albumin. This study aimed to evaluate the diagnostic ability of the ALBI score for determining hepatic fibrosis stage and transplant-free survival in primary biliary cholangitis (PBC) patients. A total of 181 Japanese patients with biopsy-proven or serologically diagnosed PBC were enrolled. The pathological stage was assessed using the Scheuer classification. The ALBI score differentiated fibrosis in stage 4 from that of 3 in the biopsy-proven cohort ( p 0.05). With an ALBI score cut-off value of ?1.679, the sensitivity and specificity were 100% and 91.1%, respectively, with a likelihood ratio of 12.3 to differentiate stage 4 from stages 1–3. The ALBI score at the beginning of ursodeoxycholic acid (UDCA) prescription correlated with the two prognostic scores calculated after 1-year UDCA treatment. Kaplan–Meier analysis showed that the baseline ALBI score differentiated liver transplant-free survival ( p 0.05). The ALBI score presented a greater hazard ratio for transplant-free survival than aspartate aminotransferase-to-platelet ratio index (APRI) in Cox proportional hazard model. In conclusion, ALBI score indicates pathological stage in Japanese PBC patients and scores before UDCA prescription predict better liver transplant-free survival, which correlated well with the two major prognostic scores. The prognosis-predicting ability of the ALBI score might surpass that of APRI.
机译：白蛋白-胆红素（ALBI）等级是使用ALBI评分定义的，ALBI评分是根据总血清胆红素和白蛋白计算得出的。这项研究旨在评估ALBI评分在确定原发性胆源性胆管炎（PBC）患者肝纤维化分期和无移植生存中的诊断能力。共有181名经活检证实或经血清学诊断为PBC的日本患者入选。使用Scheuer分类法评估病理阶段。在活检证实的队列中，ALBI评分将第4阶段的纤维化与3阶段的纤维化区分开（p <0.05）。 ALBI得分的截断值为1.679，敏感性和特异性分别为100％和91.1％，将第4阶段与第1-3阶段区分开来的似然比为12.3。熊去氧胆酸（UDCA）处方开始时的ALBI评分与UDCA治疗1年后计算的两个预后评分相关。 Kaplan–Meier分析显示，基线ALBI评分可区分无肝移植生存期（p <0.05）。在Cox比例风险模型中，ALBI得分显示的无移植生存风险比天冬氨酸氨基转移酶与血小板之比指数（APRI）高。总之，ALBI评分表示日本PBC患者的病理分期，而UDCA处方之前的评分可预测更好的无肝移植生存，这与两个主要的预后评分密切相关。 ALBI评分的预后预测能力可能超过APRI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号